Antifungals US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Antifungals. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Antifungals US Medical PG Question 1: You are taking care of a patient with renal failure secondary to anti-fungal therapy. The patient is a 66-year-old male being treated for cryptococcal meningitis. This drug has a variety of known side effects including acute febrile reactions to infusions, anemia, hypokalemia and hypomagnesemia. What is the mechanism of action of this drug?
- A. Inhibition of squalene epoxidase
- B. Binding of the 50S subunit
- C. Pore formation secondary to ergosterol binding (Correct Answer)
- D. Disruption of microtubule formation
- E. Inhibition of 1,3-beta-glucan synthase
Antifungals Explanation: ***Pore formation secondary to ergosterol binding***
- This describes the mechanism of action of **amphotericin B**, the antifungal agent used for cryptococcal meningitis.
- Amphotericin B binds to **ergosterol** in the fungal cell membrane, leading to the formation of pores, disruption of membrane integrity, and ultimately cell death.
- The side effects described—**nephrotoxicity with renal failure, hypokalemia, and hypomagnesemia**—are classic adverse effects of amphotericin B due to its effect on renal tubular cells and electrolyte wasting.
*Inhibition of squalene epoxidase*
- This is the mechanism of action for **terbinafine**, an antifungal primarily used for dermatophyte infections (e.g., onychomycosis), not systemic infections like cryptococcal meningitis.
- Terbinafine inhibits ergosterol synthesis at an earlier step but does not cause the severe nephrotoxicity and electrolyte disturbances described.
*Binding of the 50S subunit*
- This mechanism of action is characteristic of **macrolide antibiotics** like azithromycin or clarithromycin, which are antibacterial agents, not antifungals.
- These drugs inhibit bacterial protein synthesis and are ineffective against fungal infections.
*Disruption of microtubule formation*
- This is the mechanism of action for **griseofulvin**, an antifungal drug used for dermatophyte infections of the skin, hair, and nails.
- Griseofulvin interferes with fungal cell division and is not used for life-threatening systemic infections like cryptococcal meningitis.
*Inhibition of 1,3-beta-glucan synthase*
- This mechanism is associated with **echinocandins** (e.g., caspofungin, micafungin), which inhibit fungal cell wall synthesis.
- While echinocandins are used for some systemic fungal infections (particularly Candida and Aspergillus), they do not typically cause the severe renal failure and electrolyte disturbances characteristic of amphotericin B.
Antifungals US Medical PG Question 2: A 37-year-old woman with a history of anorectal abscesses complains of pain in the perianal region. Physical examination reveals mild swelling, tenderness, and erythema of the perianal skin. She is prescribed oral ampicillin and asked to return for follow-up. Two days later, the patient presents with a high-grade fever, syncope, and increased swelling. Which of the following would be the most common mechanism of resistance leading to the failure of antibiotic therapy in this patient?
- A. Intrinsic absence of a target site for the drug
- B. Use of an altered metabolic pathway
- C. Production of beta-lactamase enzyme (Correct Answer)
- D. Altered structural target for the drug
- E. Drug efflux pump
Antifungals Explanation: ***Production of beta-lactamase enzyme***
- The patient's symptoms of a rapidly worsening infection despite ampicillin treatment suggest the presence of a **beta-lactamase producing organism**. Ampicillin is a **beta-lactam antibiotic** that is inactivated by these enzymes.
- Anorectal abscesses and rapidly progressing soft tissue infections are often caused by **polymicrobial flora**, including staphylococci and enterococci, many of which can produce **beta-lactamase**.
*Intrinsic absence of a target site for the drug*
- While some bacteria inherently lack the target site for certain drugs (e.g., mycoplasma lacking a cell wall, thus being resistant to beta-lactams), this is less likely to be the **most common mechanism of acquired resistance** leading to treatment failure in a typical perianal infection.
- The rapid progression and failed initial treatment point towards an **acquired mechanism of resistance** rather than an intrinsic one.
*Use of an altered metabolic pathway*
- This mechanism, such as altered **folate synthesis pathways** in resistance to trimethoprim-sulfamethoxazole, is less common as the primary mechanism for ampicillin resistance.
- Ampicillin's mechanism of action primarily targets the **bacterial cell wall**, not a metabolic pathway in the same way.
*Altered structural target for the drug*
- This involves modifications to the **penicillin-binding proteins (PBPs)**, which are the targets of beta-lactam antibiotics like ampicillin. While a valid mechanism (e.g., in MRSA), the **production of beta-lactamase** is generally a more widespread and common cause of ampicillin failure, especially in infections involving mixed flora from the perianal region.
- Given the abrupt failure of ampicillin, **beta-lactamase inactivation** is a more immediate and common cause than a rapid mutational change in PBPs.
*Drug efflux pump*
- **Efflux pumps** actively remove antibiotics from the bacterial cell, contributing to resistance against various drug classes.
- While efflux pumps can play a role, the dominant mechanism for resistance to **ampicillin** in many common perianal pathogens is the **enzymatic degradation by beta-lactamases**.
Antifungals US Medical PG Question 3: An 18-year old college freshman presents to his university clinic because he has not been feeling well for the past two weeks. He has had a persistent headache, occasional cough, and chills without rigors. The patient’s vital signs are normal and physical exam is unremarkable. His radiograph shows patchy interstitial lung infiltrates and he is diagnosed with atypical pneumonia. The patient is prescribed azithromycin and takes his medication as instructed. Despite adherence to his drug regimen, he returns to the clinic one week later because his symptoms have not improved. The organism responsible for this infection is likely resistant to azithromycin through which mechanism?
- A. Mutation in topoisomerase II
- B. Methylation of ribosomal binding site
- C. Presence of a beta-lactamase
- D. Decreased binding to RNA polymerase
- E. Insertion of drug efflux pumps (Correct Answer)
Antifungals Explanation: ***Insertion of drug efflux pumps***
- **Azithromycin** is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the **50S ribosomal subunit**.
- In **Mycoplasma pneumoniae** (the most common cause of atypical pneumonia in young adults), the **most common** mechanism of macrolide resistance is through **efflux pumps**, particularly the **mef genes**.
- These efflux pumps actively transport macrolides out of the bacterial cell, reducing intracellular drug concentration and conferring resistance.
- This mechanism is responsible for the majority of macrolide-resistant *M. pneumoniae* isolates worldwide.
*Methylation of ribosomal binding site*
- **Methylation** of the ribosomal binding site (specifically the **23S rRNA** via erm genes) does prevent azithromycin from binding effectively.
- While this is a valid macrolide resistance mechanism seen in organisms like *Streptococcus pneumoniae* and *Streptococcus pyogenes*, it is **less common** in *Mycoplasma pneumoniae*.
- Efflux pumps (mef) are the predominant mechanism in *M. pneumoniae* resistant strains.
*Mutation in topoisomerase II*
- **Topoisomerase II** (DNA gyrase) is the target of **fluoroquinolone antibiotics**, not macrolides.
- Mutations in this enzyme lead to resistance against fluoroquinolones, such as **ciprofloxacin**.
*Presence of a beta-lactamase*
- **Beta-lactamase enzymes** inactivate **beta-lactam antibiotics** (e.g., penicillin, cephalosporins) by hydrolyzing their beta-lactam ring.
- Additionally, *Mycoplasma pneumoniae* **lacks a cell wall**, making it inherently resistant to all beta-lactam antibiotics regardless of beta-lactamase production.
*Decreased binding to RNA polymerase*
- **RNA polymerase** is the target for antibiotics like **rifampin**, which inhibits bacterial transcription.
- Decreased binding to RNA polymerase would lead to rifampin resistance, not azithromycin resistance.
Antifungals US Medical PG Question 4: A 57-year-old florist presents to his family physician with nodular lesions on his right hand and forearm. He explains that he got pricked by a rose thorn on his right "pointer finger" where the first lesions appeared, and the other lesions then began to appear in an ascending manner. The physician prescribed a medication and warned him of gynecomastia as a side effect if taken for long periods of time. Which of the following is the mechanism of action of the medication?
- A. Inhibits squalene epoxidase
- B. Binds to ergosterol, forming destructive pores in cell membrane
- C. Disrupts microtubule function
- D. Inhibits ergosterol synthesis (Correct Answer)
- E. Inhibits formation of beta glucan
Antifungals Explanation: ***Inhibits ergosterol synthesis***
- The clinical presentation of **nodular lesions** on the hand and forearm in an **ascending manner** after a rose thorn prick is characteristic of **sporotrichosis**, caused by *Sporothrix schenckii*.
- **Itraconazole** is the treatment of choice for sporotrichosis, and it works by **inhibiting ergosterol synthesis** via the inhibition of **lanosterol 14-alpha-demethylase**. Gynecomastia is a known side effect of long-term itraconazole use.
*Inhibits squalene epoxidase*
- This is the mechanism of action of **terbinafine**, another antifungal agent.
- While terbinafine is used for some fungal infections, it is **not the first-line treatment for sporotrichosis** and is not typically associated with gynecomastia as a common side effect.
*Binds to ergosterol, forming destructive pores in cell membrane*
- This describes the mechanism of action of **amphotericin B** and **nystatin**.
- Amphotericin B is used for severe systemic fungal infections, but sporotrichosis typically responds well to oral itraconazole, and amphotericin B is reserved for severe or disseminated cases.
*Disrupts microtubule function*
- This is the mechanism of action of **griseofulvin**, an antifungal agent primarily used for dermatophyte infections of the skin, hair, and nails.
- It is **not effective against *Sporothrix schenckii*** and is not associated with the clinical scenario described.
*Inhibits formation of beta glucan*
- This is the mechanism of action of **echinocandins** (e.g., caspofungin, micafungin, anidulafungin).
- Echinocandins are effective against *Candida* and *Aspergillus* species but have **limited activity against dimorphic fungi** like *Sporothrix schenckii*.
Antifungals US Medical PG Question 5: A 74-year-old man is admitted to the medical ward after he developed a fungal infection. He has aplastic anemia. The most recent absolute neutrophil count was 450/µL. An anti-fungal agent is administered that inhibits the fungal enzyme, (1→3)-β-D-glucan synthase, and thereby disrupts the integrity of the fungal cell wall. He responds well to the treatment. Although amphotericin B is more efficacious for his condition, it was not used because of the side effect profile. What was the most likely infection?
- A. Invasive aspergillosis
- B. Mucormycosis
- C. Histoplasmosis
- D. Paracoccidioidomycosis
- E. Candidemia (Correct Answer)
Antifungals Explanation: ***Candidemia***
- The patient's **neutropenia** (absolute neutrophil count of 450/µL) due to aplastic anemia is a major risk factor for invasive candidiasis, including candidemia.
- The antifungal agent's mechanism of action, targeting **(1→3)-β-D-glucan synthase**, is characteristic of **echinocandins**, which are first-line agents for candidemia, especially in critically ill or neutropenic patients, and often preferred over amphotericin B due to a better side effect profile.
*Invasive aspergillosis*
- While neutropenia is a significant risk factor for invasive aspergillosis, the primary antifungal drugs for this condition are typically **voriconazole** or **isavuconazole**, although echinocandins may be used as salvage therapy or in combination.
- The description of the drug's mechanism specifically targeting **(1→3)-β-D-glucan synthase** does not make aspergillosis the *most likely* infection, as some Aspergillus species may have less β-D-glucan in their cell walls compared to *Candida*.
*Mucormycosis*
- This aggressive fungal infection is often seen in immunocompromised patients, particularly those with **diabetes** or profound neutropenia, but the primary treatment is usually **amphotericin B**.
- Mucorales fungi typically **lack ergosterol** and their cell walls do not contain **(1→3)-β-D-glucan**, making echinocandins ineffective.
*Histoplasmosis*
- This is a dimorphic fungal infection endemic to certain geographic regions, primarily affecting the lungs and disseminating in immunocompromised individuals.
- The drug of choice for severe or disseminated histoplasmosis is **amphotericin B**, followed by azoles; echinocandins are generally not active against *Histoplasma*.
*Paracoccidioidomycosis*
- This is a chronic systemic mycosis found in Latin America, primarily affecting the lungs, skin, and lymph nodes.
- Treatment for severe forms typically involves **amphotericin B**, followed by sulfonamides or azoles for maintenance; echinocandins are not effective against *Paracoccidioides*.
More Antifungals US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
